Press Releases

Biocon Biologics  /  Press Releases

Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%

  • Posted by: Biocon Biologics

Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award

  • Posted by: Biocon Biologics

Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil

  • Posted by: Biocon Biologics

Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets

Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
  • Posted by: Biocon Biologics

Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer

Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
  • Posted by: Biocon Biologics

Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)

Biocon Biologics and Viatris Inc Receive CHMP Nod for Abevmy a Biosimilar to Avastin Bevacizumab
  • Posted by: Biocon Biologics

Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide

Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care
  • Posted by: Biocon Biologics

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries
  • Posted by: Biocon Biologics

Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore

Biocon Q3FY21 Results
  • Posted by: Biocon Biologics

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
  • Posted by: Biocon Biologics
Share